DR. DAVID B AGUS, M.D.
Osteopathic Medicine at Wilshire Blvd, Beverly Hills, CA
License number
California G85631
Category
Medical Practice
Type
Specialist
License number
California G85631
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2
9033 Wilshire Blvd SUITE 300, Beverly Hills, CA 90211
PO Box 31309, Los Angeles, CA 90031
PO Box 31309, Los Angeles, CA 90031
Phone
(323) 865-3105
(323) 865-0061 (Fax)
(323) 865-0061 (Fax)
Personal information
See more information about DAVID B AGUS at radaris.comName
Address
Phone
522 N Crescent Dr, Beverly Hills, CA 90210
N Beverly Dr, Beverly Hills, CA 90210
522 Crescent Dr, Beverly Hills, CA 90210
8700 Beverly Blvd, West Hollywood, CA 90048
Professional information
David Agus
Location:
Greater Los Angeles Area
Industry:
Medical Practice
Skills:
Clinical Research, Healthcare, Lifesciences, Genomics, Biotechnology, Molecular Biology, Research, Oncology, Strategic Planning, Public Health, Cancer, Healthcare Information Technology, Cell Biology, Epidemiology, Cell Culture, Proteomics, Clinical Trials, Immunology, Genetics, Biochemistry, Medicine, Neuroscience, Internal Medicine, Protein Chemistry, Science, Infectious Diseases, Hardware Diagnostics, Medical Education, Informatics, Medical Devices, Bioinformatics
David B Agus, Beverly Hills CA
Specialties:
Internal Medicine, Hematology & Oncology, Medical Oncology, Public Health & General Preventive Medicine
Work:
USC Westside Prostate Cancer Ctr
9033 Wilshire Blvd, Beverly Hills, CA 90211
9033 Wilshire Blvd, Beverly Hills, CA 90211
Education:
Raymond & Ruth Perelman Sch of Med at Univ of PA, Philadelphia, PA (1992), Mem Sloan-Kettering Cancer Ctr 1994-1996 *
David B Agus, Beverly Hills CA
Specialties:
Internist
Address:
9033 Wilshire Blvd, Beverly Hills, CA 90211
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine
Method Of Screening For Sensitivity To Kinase Inhibitor Therapy
US Patent:
7803546, Sep 28, 2010
Filed:
Feb 23, 2007
Appl. No.:
11/678420
Inventors:
David B. Agus - Beverly Hills CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 1/68, G01N 33/574, C07H 21/00
US Classification:
435 6, 435 721, 435 723, 536 231
Abstract:
Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.
Bi-Directional System For Mass Spectrometry
US Patent:
7816647, Oct 19, 2010
Filed:
Feb 28, 2006
Appl. No.:
11/816899
Inventors:
David B. Agus - Beverly Hills CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
H01J 49/26, H01J 49/36
US Classification:
250291, 250281, 250282, 250285
Abstract:
The present invention relates to a system and method for mass spectrometry () that allows for bi-directional introduction of collections of charged particles into the magnetic field of a mass spectrometer. More particularly, the present invention includes a system for mass spectrometry () (e. g. , an FTMS mass spectrometer) with a cylindrical magnet () configured to receive and measure the cyclotron frequencies () of charged particles that are introduced () into the cylindrical magnet () from either of the two axial ends thereof. Methods of the invention relate to performing mass spectrometry analysis on collections of charged particles that are introduced (), serially, simultaneously or both, into a cylindrical magnet () from opposing axial ends thereof. The present invention exhibits significantly increased magnet throughput relative to currently available devices, by allowing flow in the opposite direction to a second detector, e. g. , during ion processing time of a first detector.
Gene Expression Markers For Response To Egfr Inhibitor Drugs
US Patent:
2005016, Jul 28, 2005
Filed:
May 28, 2004
Appl. No.:
10/857715
Inventors:
David Agus - Beverly Hills CA, US
Joffre Baker - Montara CA, US
Ron Natale - Santa Monica CA, US
Steven Shak - Hillsborough CA, US
Joffre Baker - Montara CA, US
Ron Natale - Santa Monica CA, US
Steven Shak - Hillsborough CA, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Methods Of Diagnosis Of Prostate Cancer, Compositions And Methods Of Screening For Modulators Of Prostate Cancer
US Patent:
2010029, Nov 25, 2010
Filed:
Dec 30, 2008
Appl. No.:
12/345877
Inventors:
David B. Agus - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 39/395, C12Q 1/68, G01N 33/68, C07H 21/04, C12N 15/63, C12N 5/10, C07K 2/00, C07K 16/46, C07K 16/18, C40B 40/06, A61P 35/00
US Classification:
4241741, 435 6, 435 71, 536 231, 4353201, 435325, 530300, 530350, 5303873, 5303891, 436 86, 506 16
Abstract:
Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.
Gene Expression Markers For Response To Egfr Inhibitor Drugs
US Patent:
2008031, Dec 25, 2008
Filed:
Dec 3, 2007
Appl. No.:
11/949535
Inventors:
David AGUS - Beverly Hills CA, US
Joffre B. Baker - Montara CA, US
Ron B. Natale - Santa Monica CA, US
Steven Shak - Hillsborough CA, US
Joffre B. Baker - Montara CA, US
Ron B. Natale - Santa Monica CA, US
Steven Shak - Hillsborough CA, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Erbb Antagonists For Pain Therapy
US Patent:
2006003, Feb 16, 2006
Filed:
Apr 7, 2005
Appl. No.:
11/102120
Inventors:
David Agus - Beverly Hills CA, US
International Classification:
A61K 39/395
US Classification:
424143100
Abstract:
The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.
Diagnosis Of Zd1839 Resistant Tumors
US Patent:
2005005, Mar 17, 2005
Filed:
Jul 31, 2003
Appl. No.:
10/633486
Inventors:
Daniel Afar - Fremont CA, US
David Agus - Beverly Hills CA, US
David Mack - Menlo Park CA, US
David Agus - Beverly Hills CA, US
David Mack - Menlo Park CA, US
International Classification:
C12Q001/68, C07H021/04, C12N009/00
US Classification:
435006000, 435069100, 435183000, 435320100, 435325000, 530388260, 536023200
Abstract:
Described herein are genes whose expression are regulated in specific cancers. Related methods and compositions that can be used for diagnosis of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.